Company

Syndax Pharmaceuticals, Inc.

Headquarters: Waltham, MA, United States

Employees: 59

CEO: Mr. Michael A. Metzger M.B.A.

NASDAQ: SNDX +1.14%

Market Cap

$1.78 Billion

USD as of July 1, 2024

Market Cap History

Syndax Pharmaceuticals, Inc. market capitalization over time

Evolution of Syndax Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Syndax Pharmaceuticals, Inc.

Detailed Description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Syndax Pharmaceuticals, Inc. has the following listings and related stock indices.


Stock: NASDAQ: SNDX wb_incandescent

Stock: FSX: 1T3 wb_incandescent

Details

Headquarters:

35 Gatehouse Drive

Building D Floor 3

Waltham, MA 02451

United States

Phone: 781 419 1400

Fax: 781 419 1420